Angela Alistar

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Open-label Phase 2, Hepatology, Medicine +8

Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein

Andrew Ferretti, Tomasz Kula, Yifan Wang et al. · Immunity · 2020 · 362 citations · Full text

Spike Protein, Adaptive Immune System, Largely Reside +6

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial

Angela Alistar, Bonny Morris, Rodwige Desnoyer et al. · The Lancet Oncology · 2017 · 221 citations · Full text

Pancreatic Cancer, Modified Folfirinox, Medicine +9

Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness

Lance D. Miller, Jeff Chou, Michael A. Black et al. · Cancer Immunology Research · 2016 · 103 citations · Full text

A Phase III Open-Label Trial to Evaluate Efficacy and Safety of CPI-613 Plus Modified FOLFIRINOX (MFFX) versus FOLFIRINOX (FFX) in Patients with Metastatic Adenocarcinoma of the Pancreas

Philip A. Philip, Marc Buyse, Angela Alistar et al. · Future Oncology · 2019 · 94 citations